Bromantane vs MK-677
Moderate Research vs Well Studied
avoid Mechanism-based · 64% Both Bromantane and MK-677 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.
Molecular Data
Bromantane MK-677
Weight 277.18 Da 624.77 Da
Half-life ~11 hours ~24 hours
Type Adamantane-bromophenyl derivative (C16H20BrN) Non-peptide ghrelin receptor agonist
Key Benefits
Bromantane
01 Upregulates endogenous dopamine synthesis via tyrosine hydroxylase gene expression, producing sustained motivational drive without depletion
02 Anxiolytic properties reduce stress and anxiety without sedation, creating a state of calm, focused energy
03 Actoprotective effects improve both physical and mental performance under stressful or fatiguing conditions
04 Very low abuse and dependence potential due to the absence of acute monoamine release or reuptake inhibition
05 Minimal tolerance development compared to traditional stimulants, supporting longer-term use patterns
06 Smooth onset and offset with no crash or rebound effects
MK-677
01 97% increase in 24-hour growth hormone secretion
02 40-72% elevation in IGF-1 levels
03 Enhanced sleep quality with improved REM patterns
04 Preferential lean tissue gains of 1.1-2.7kg over 8-12 months
05 15% basal metabolic rate increase within 2 weeks
06 Oral administration (no injections required)
Side Effects
Bromantane
Insomnia or difficulty falling asleep (if taken too late in the day)
Mild anxiety or restlessness at higher doses (above 100 mg)
Mild headache (uncommon, typically transient)
MK-677
Appetite stimulation (>50% of users)
Water retention (30-40%)
Lethargy (20-30%)
Fasting glucose elevation (5-15mg/dL)
Note on testosterone suppression: at doses up to 20 mg daily, MK-677 is unlikely to cause significant testosterone suppression on its own. Above 20 mg daily, the likelihood of suppression and other side effects (insulin resistance, water retention, lethargy) increases. The case report documenting 85.7% testosterone suppression involved co-administration with LGD-4033, a SARM known to be profoundly suppressive, making the SARM the likely primary driver of that suppression.
Contraindications
Known hypersensitivity to bromantane or adamantane derivatives
Pregnancy and breastfeeding (insufficient safety data)
Severe hepatic impairment
Concurrent use of MAO inhibitors (theoretical risk of excessive dopaminergic activity)
Heart disease or congestive heart failure
Diabetes or pre-diabetes
Active cancer
Severe cardiovascular disease
Pregnancy or breastfeeding
Research Evidence
Bromantane MK-677
Status Moderate Research Well Studied
References 5 studies 7 studies
Latest — July 2024
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.